Neurocrine Biosciences, Inc. (NBIX)
168.45
-0.95
(-0.56%)
USD |
NASDAQ |
Nov 13, 09:56
Neurocrine Biosciences Free Cash Flow (Quarterly) : 375.40M for Sept. 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 375.40M |
| June 30, 2026 | 70.20M |
| March 31, 2026 | 136.70M |
| December 31, 2025 | 390.80M |
| September 30, 2025 | 214.30M |
| June 30, 2025 | 89.50M |
| March 31, 2025 | 54.10M |
| December 31, 2024 | 235.20M |
| September 30, 2024 | 149.90M |
| June 30, 2024 | 53.00M |
| March 31, 2024 | 119.10M |
| December 31, 2023 | 118.10M |
| September 30, 2023 | 204.40M |
| June 30, 2023 | 172.80M |
| March 31, 2023 | -133.70M |
| December 31, 2022 | 141.20M |
| September 30, 2022 | 100.50M |
| June 30, 2022 | 129.30M |
| March 31, 2022 | -48.10M |
| December 31, 2021 | -4.70M |
| September 30, 2021 | 56.10M |
| June 30, 2021 | 98.90M |
| March 31, 2021 | 82.80M |
| December 31, 2020 | 84.40M |
| September 30, 2020 | -17.90M |
| Date | Value |
|---|---|
| June 30, 2020 | 114.20M |
| March 31, 2020 | 36.90M |
| December 31, 2019 | 99.74M |
| September 30, 2019 | 94.28M |
| June 30, 2019 | 59.71M |
| March 31, 2019 | -116.43M |
| December 31, 2018 | 44.44M |
| September 30, 2018 | 56.56M |
| June 30, 2018 | 15.84M |
| March 31, 2018 | -40.29M |
| December 31, 2017 | 38.20M |
| September 30, 2017 | -12.11M |
| June 30, 2017 | -48.64M |
| March 31, 2017 | -78.72M |
| December 31, 2016 | -31.97M |
| September 30, 2016 | -31.79M |
| June 30, 2016 | -16.58M |
| March 31, 2016 | -29.95M |
| December 31, 2015 | -16.03M |
| September 30, 2015 | -18.89M |
| June 30, 2015 | 13.45M |
| March 31, 2015 | -18.46M |
| December 31, 2014 | -15.75M |
| September 30, 2014 | -12.37M |
| June 30, 2014 | -10.61M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Amgen, Inc. | 3.654B |
| Halozyme Therapeutics, Inc. | 255.22M |
| BioCryst Pharmaceuticals, Inc. | 32.46M |
| Iovance Biotherapeutics, Inc. | -9.306M |
| Precigen, Inc. | 11.45M |